Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05911425
Other study ID # IRB-2023-222
Secondary ID
Status Not yet recruiting
Phase Phase 2
First received
Last updated
Start date July 1, 2023
Est. completion date June 30, 2025

Study information

Verified date June 2023
Source Zhejiang Cancer Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study will evaluate the efficacy and safety of envelizumab in combination with sovalteinib in the treatment of treated bile duct cancer, and explore treatment options to improve patient survival, while the study will attempt to explore the characteristics of the population benefiting from the treatment, and construct a preliminary efficacy prediction model by detecting markers in blood to provide a theoretical basis for implementing precise treatment.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 30
Est. completion date June 30, 2025
Est. primary completion date June 30, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. the patient is 18-75 years old, can fully understand the content of this study, voluntarily join this study and cooperate with the study, and has full civil capacity 2. have a histologically or cytologically confirmed diagnosis of bile duct cancer 3. Patients with cholangiocarcinoma who have previously failed (disease progression or intolerability) to receive first-line or higher standard-containing therapy, including but not limited to chemotherapy, immunotherapy, targeted therapy, etc.; or who have relapsed within 6 months of postoperative adjuvant therapy; 4. patients receiving the first dose of this study at an interval of = 28 days from the last treatment; 5. having a measurable lesion (=10 mm long diameter on CT scan for non-lymph node lesions and =15 mm short diameter on CT scan for lymph node lesions according to RECIST 1.1 criteria) 6. an ECOG PS score: 0 to 1; 7. subjects voluntarily enrolled in this study, with good compliance and cooperation with safety and survival follow-up. 8. have adequate organ function and have not had a blood transfusion, used granulocyte colony-stimulating factor (G-CSF), or used medication within 7 days prior to screening to correct: 1) Blood count: Absolute Neutrophil Count (ANC) 1.5 × 109/L, Platelet (PLT) = 70 × 109/L, Hemoglobin (HGB) = 90 g/L; 2) Liver function: serum total bilirubin (Total Bilirubin, TBIL) = 1.5 × Upper Limit of Normal Value (ULN); Alanine Aminotransferase (ALT) and Aspartate Transferase (AST) =3×ULN; serum albumin =28 g/L; Alkaline Phosphatase (ALP) =5×ULN; after conventional hepatoprotective treatment meeting the above criteria, and can be stable for at least 1 week after evaluation by the investigator can be enrolled; 3) Renal function: serum creatinine (Cr) = 1.5 × ULN, or creatinine clearance = 50 mL/mi (applying the standard Cockcroft-Gault formula); (4) Coagulation: International Normalized Ratio (INR) = 1.5 /PT = 1.5 × ULN, aPTT = 1.5 × ULN; (5) nutritional status: body mass index BMI = 18 kg/m2, weight = 40 kg, serum albumin = 3.0 g/dL; 9. life expectancy = 6 months. Exclusion Criteria: 1. subjects with prior or concurrent other malignancies, including combined or mixed hepatocellular/cholangiocarcinoma or potbelly cancer; 2. active brain metastases or spinal cord compression; 3. not having received systemic antitumor therapy prior to the first study drug treatment 4. prior antitumor therapy-related toxicity not recovered to CTCAE = grade 1, except for alopecia and platinum-induced peripheral neuropathy = grade 2 5. prior liver transplantation; 6. the subject has known prior hypersensitivity to macromolecular protein agents or drug components of sovalteinib 7. subject has any active autoimmune disease or history of autoimmune disease (e.g., the following, but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, enterocolitis, pituitary inflammation, vasculitis, nephritis, hyperthyroidism, hypothyroidism, previous thyroid surgery cannot be included; subject has vitiligo or asthma that has completely resolved in childhood and does not require any intervention in adulthood (subjects with vitiligo or asthma that has been in complete remission in childhood and does not require any intervention as an adult may be included; subjects with asthma requiring medical intervention with bronchodilators are not included); 8. subjects who are on immunosuppressive, immunomodulatory, or systemic, or absorbable topical hormone therapy for immunosuppressive purposes (doses >10 mg/day of prednisone or other equipotent hormone) and who continue to use them within 2 weeks prior to enrollment 9. clinically symptomatic ascites or pleural effusion that is not controlled by medication and requires therapeutic puncture or drainage prior to the first study drug therapy; 10. have had major surgical procedures or surgical incisions that have not fully healed prior to the first dose of the drug 11. patients with clinical cardiac symptoms or disease that are not well controlled, such as (1) NYHA class 2 or higher heart failure (2) unstable angina pectoris (3) myocardial infarction within 1 year (4) patients with clinically significant supraventricular or ventricular arrhythmias requiring treatment or intervention; 12. subjects with active infection or unexplained fever >38.5 degrees during screening and prior to the first dose (subjects with fever arising from tumors may be enrolled, as determined by the investigator) 13. patients with a history of prior and current objective evidence of pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonia, drug-related pneumonia, or severely impaired lung function 14. live vaccines administered less than 4 weeks prior to study drug administration or likely to be administered during the study period 15. subjects with a known history of psychotropic substance abuse, alcoholism, or drug use 16. women who are pregnant or breastfeeding; 17. are of childbearing potential but unwilling to accept effective contraception 18. subjects who, in the opinion of the investigator, should be excluded from this study, for example, subjects who, in the judgment of the investigator, have other factors that might force the study to be terminated mid-study, such as, other serious illnesses (including psychiatric illnesses) requiring comorbid treatment, serious laboratory test abnormalities, accompanying family or social factors that would compromise the safety of the subject, or data and sample collection.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
envolizumab , sovalteinib
Envolizumab 300mg, Q2W, day 1, subcutaneous injection Soventinib 200mg, Q2W, once daily, orally Every 2 weeks as a cycle.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Zhejiang Cancer Hospital

Outcome

Type Measure Description Time frame Safety issue
Primary ORR Proportion of patients whose tumors shrink by a certain amount and remain for a certain period of time through disease progression, an average of 6 months
Secondary DoR The time from the first evaluation of the tumor as CR or PR to the first evaluation of PD (Progressive Disease) or death from any cause through disease progression, an average of 6 months
Secondary DCR Time from the start of the first evaluation of the tumor as CR, PR or SD to the first evaluation of PD (Progressive Disease) or death from any cause through disease progression, an average of 6 months
Secondary PFS Time from treatment initiation to first tumor progression or death through disease progression, an average of 1 6 months
Secondary OS Time from the start of treatment to death from any cause through patient death, an average of 1 year
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Recruiting NCT02954302 - Proximal Roux-en-y Gastrojejunal Anastomosis on Delayed Gastric Emptying After Pylorus-resecting Pancreaticoduodenectomy N/A
Active, not recruiting NCT01954745 - A Phase II Study of Cabozantinib (XL-184) Monotherapy in Patients With Advanced Cholangiocarcinoma After Progression on First or Second Line Systemic Therapy Phase 2
Recruiting NCT01439698 - Radio Frequency Ablation in the Management of Pancreatico-biliary Disorders: A Multicenter Registry N/A
Active, not recruiting NCT04164069 - Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab Phase 1
Recruiting NCT05155878 - Prognostic Factors in Periampullary Tumors and Cysts
Recruiting NCT04993131 - Liver Transplantation for Non-resectable Perihilar Cholangiocarcinoma N/A
Active, not recruiting NCT05662488 - FAPI PET for Response Evaluation and Prognosis Prediction in Liver and Biliary Cancer Patients Treated With PD-1 Combination Therapy
Completed NCT05266300 - Implementation and Quality Assurance of DPYD-genotyping in Patients Treated With Fluoropyrimidines.
Recruiting NCT04907643 - Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes N/A
Active, not recruiting NCT04853017 - A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors Phase 1
Recruiting NCT05286814 - M9241 in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer or Intrahepatic Cholangiocarcinoma Phase 2
Completed NCT02853474 - Early Palliative Care in Patients With Metastatic Upper Gastrointestinal Cancers Treated With First-line Chemotherapy Phase 3
Completed NCT00639314 - Trial on the Evaluation of Pylorus-ring in Pancreaticoduodenectomy N/A
Completed NCT04596865 - Recurrence After Whipple's (RAW) Study
Recruiting NCT05277766 - Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer Phase 1
Recruiting NCT01522573 - T-EUS for Gastrointestinal Disorders: A Multicenter Registry N/A
Enrolling by invitation NCT01111591 - Cyclooxygenase-2 Inhibitor for Adjuvant Anticancer Effect in Patients With Biliary-pancreas Cancer Phase 4
Completed NCT00779688 - A Registry of Patients Undergoing Cellvizio Endomicroscopy and Endoscopic Retrograde Cholangiopancreatography(ERCP) Imaging Procedures for Diagnosing Pancreatic and Bile Duct Cancers N/A
Active, not recruiting NCT04152018 - Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors. Phase 1